Indeterminate cystic fibrosis newborn screening results

Pediatric Pulmonology

Volumn 50, Issue 2, 2015, Pages 209-210

  Ren, Clement L ^a   Parad, Richard ^b,c   Borowitz, Drucy ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANCREAS ENZYME;

BACTERIUM CULTURE; CYSTIC FIBROSIS; DISEASE REGISTRY; DISEASE SURVEILLANCE; ENZYME REPLACEMENT; GENE MUTATION; GENOTYPE; HEALTH HAZARD; HUMAN; INFANT; LETTER; METABOLIC SYNDROME X; NEWBORN SCREENING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; THORAX RADIOGRAPHY; MEDICAL ETHICS;

CYSTIC FIBROSIS; ETHICS, MEDICAL; HUMANS; NEONATAL SCREENING;

EID: 84920997717     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23055     Document Type: Letter

References (7)

1. Massie J, Gillam L. Uncertain diagnosis after newborn screening for cystic fibrosis: and ethics-based approach to a clinical dilemma. Pediatr Pulmonol 2014;49:1-7.
2. Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, et al. Cystic fibrosis foundation practice guidelines for the management of infants with cystic fibrosis transmembrane regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009;155:S106-S116.
3. Fink A, Elbert A, Marshall B, Wagener J. Epidemiology and phenotypic variability of US patients with cystic fibrosis and the R117H mutation. Pediatr Pulmonol 2013;S36:372.
4. Massie JR, Wilcken B, Van Asperen P, Dorney S, Gruca M, Wiley V, Gaskin K. Pancreatic function and extended mutation analysis in delta F508 heterozygous infants with an elevated immunoreactive trysinogen but normal sweat chloride levels. J Pediatr 2000;137:214-220.
5. Thauvin-Robinet C, Munck A, Huet F, Génin E, Bellis G, Gautier E, Audrézet M-P, Férec C, Lalau G, Des Georges M, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009;46:752-758.
6. Parad R, Comeau A, Soultan Z, Anbar R, Pass K, Caggana M, Dorkin H, Quizon A, Waltz D, Martin M, et al. Outcomes of a cohort of immunoreactive trypsinogen (IRT)/DNA cystic fibrosis newborn screening (CFNBS) positive infants with R117H as one of two detected CFTR mutations: worrisome throat culture findings. Pediatr Pulmonol 2005;S28:256.
7. Ren CL, Desai H, Platt M, Dixon M. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 2011;46:1079-1184.